|
Apoptosis |
Programmed cell death or “cell suicide”. Apoptosis normally occurs as part of the body’s natural growth, maintenance and tissue renewal processes. Under certain circumstances, e.g. in the tissue surrounding a brain haemorrhage, this process can become uncontrolled and lead to widespread tissue cell death.
|
|
Arteriovenous malformation |
A knot of distended blood vessels often overlying and compressing the surface of the brain. |
|
CE Mark |
A European standard for medical devices, a CE Mark indicates that a device meets the requirements of the Medical Device Directive and appropriate Quality System standards. |
|
Chemoembolisation |
Embolisation incorporating a chemotherapy drug |
|
CIRSE |
The Cardiovascular and Interventional Radiological Society of Europe |
|
Conventional TACE |
Trans-Arterial Chemo-Embolisation - a procedure whereby a chemotherapeutic agent is mixed into slurry and injected via a catheter, locally at a tumour site. |
|
DC Bead®
|
DC Bead® is an embolic Drug-Eluting Bead capable of loading and releasing in a controlled manner chemotherapeutic agents. |
|
DC BeadM1™ |
DC BeadM1™ has been developed with a narrower distribution and offers the proven benefits of DC Bead® to more patients. |
|
DEBDOX®
|
Treatment involving DC Bead® with doxorubicin
|
|
DEBIRI® |
Treatment involving the DC Bead® with Irinotecan |
|
Doxorubicin |
A widely used chemotherapeutic agent for the treatment of a large number of cancers. It is a powerful cytotoxic drug that is not cell cycle specific. |
|
Drug-Eluting Beads |
Polymer embolisation microspheres designed to load and elute drugs. |
|
Drug-Eluting Irinotecan Bead Clinical Trials |
A family of clinical trials sponsored by Biocompatibles for the evaluation of Drug-Eluting Beads for the treatment of hepatic colorectal metastases. |
|
Embolisation |
The introduction of material to reduce or completely obstruct bloodflow. |
|
FDA |
The United States Food and Drug Administration, which regulates drugs and medical devices. |
|
FOLFIRI |
A chemotherapy regimen for the treatment of colorectal cancer, made up of the drug FOLinic Acid (Leucovorin), Fluorouracil (5-FU) and IRInotecan (Camptosar). |
|
HCC |
Hepatocellular carcinoma, primary tumour of the liver. |
|
Hepatic colorectal metastases |
Colorectal cancer that has spread to the liver. |
|
Hypervascular tumour |
A growth of tissue with an abnormally increased blood supply which may be malignant or benign. |
|
IDE |
Investigational Device Exemption - The approval by the FDA to carry out a clinical trial in the US with an unapproved device. |
|
Interventional Oncology |
Interventional oncology is the treatment of cancer and cancer-related problems using minimally invasive, targeted treatments performed under imaging guidance. |
|
Irinotecan |
A widely used chemotherapeutic agent for the treatment of colorectal cancer. It is a topoisomerase I inhibitor that interferes with DNA replication during cell division, leading to cell death. |
|
LC Bead™
|
LC Bead™ is intended for the embolisation of hypervascularised tumours and arteriovenous malformation. LC Bead™ has 510k clearance from the FDA.
|
|
LC BeadM1™ |
LC BeadM1™ has been developed with a narrower distribution and offers the benefits of LC Bead™ to more patients. |
|
Metastatic disease |
The spread of a cancer from its original site (primary) to other locations within the body (secondary). In the case of colorectal cancer, the liver is the most common site of secondary tumours. |
|
mCRC |
Metastatic Colorectal Cancer is cancer of the colon or rectum that has spread, or metastasised to other parts of the body, such as the liver or lung. |
|
Nexavar® (sorafenib) |
Nexavar is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC). |
|
PARAGON Bead™ |
Biocompatibles' proprietary irinotecan HCl, drug-eluting bead. |
|
PARAGON I |
PARAGON I is in hepatic colorectal metastases; Randomised controlled trial; Safety & Efficacy; 70 patients; multi-centre; United States; FDA approved |
|
PRECISION Bead™ |
Biocompatibles' proprietary Drug-Eluting Bead product containing doxorubicin. |
|
PRECISION Clinical Trials |
A family of clinical trials for the evaluation of the Drug-Eluting Beads with doxorubicin. |
|
PRECISION TACE |
The use of either PRECISION Bead or DC Bead in the TACE procedure. PRECISION TACE results in a lower systemic drug exposure and more drug at the tumour site. |
|
Pre-loaded Bead |
A Drug-Eluting Bead incorporating a drug which has been loaded into the Bead in Biocompatibles' facility. |
|
Systemic chemotherapy |
Treatment with anticancer drugs that travel through the bloodstream, reaching and affecting cells all over the body. |
|
Tumour Response |
A measurement of the effect of a treatment on a tumour:
Complete Response - Disappearance of the targeted lesion
Partial Response - Greater than 30-50% (depending on evaluation method) reduction in the targeted lesion
Progressive Disease - Greater than 20-25% (depending on evaluation method) increase in the targeted lesion
Stable Disease - All other cases
Objective Response - Complete and Partial Response |